HC Wainwright & Co. Maintains Buy on Ekso Bionics Holdings, Lowers Price Target to $9.25
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Ekso Bionics Holdings (NASDAQ:EKSO) but lowers the price target from $10 to $9.25.

March 05, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Ekso Bionics Holdings but lowers the price target from $10 to $9.25.
While the reduction in price target might suggest a slight adjustment in valuation expectations, the maintenance of a Buy rating indicates a continued positive outlook on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the reaffirmed confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100